Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases

doi:10.3748/wjg.v19.i5.761

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6156)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

395

HTML

3196

Figures (1-2)

226

Tables (1-2)

180

Sum=3997

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1154

Download

1005

Sum=2159

Feb 7, 2013 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastroenterol. Feb 7, 2013; 19(5): 761-768
Published online Feb 7, 2013. doi: 10.3748/wjg.v19.i5.761

Open in New Tab Full Size Figure Download Figure

Figure 1 Forest plot. A: Overall morbidity; B: Severe complications; C: Overall sinusoidal dilation; D: Moderate or severe sinusoidal dilation. Bev: Bevacizumab.

Open in New Tab Full Size Figure Download Figure

Figure 2 Funnel plot of the results obtained from studies comparing overall morbidity. RR: Risk ratio.

Citation: Li DB, Ye F, Wu XR, Wu LP, Chen JX, Li B, Zhou YM. Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases. World J Gastroenterol 2013; 19(5): 761-768
URL: https://www.wjgnet.com/1007-9327/full/v19/i5/761.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i5.761